Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Кафедра психиатрии Ереванского государственного медицинского университета, Армения 2ФГБУ Московский НИИ психиатрии Минздрава РФ 3ФГБУ НИИ фармакологии им. В.В.Закусова РАМН, Москва
Список исп. литературыСкрыть список 1. Awad G, Hassan M, Loebel A et al. Evaluation of health related quality of life outcomes among patients with schizophrenia switched to lurasidone from other antipsychotics. Value Health 2013; 3 (16): 64. 2. Galderisi S, Bucci P, Mucci A et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 2013; 1 (147): 157–62. 3. Galderisi S, Mucci A, Bitter I et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 2013; 3 (23): 196–204. 4. Helldin L, Cavallaro R, Galderisi S. A functional comparison of patients with schizophrenia between the North and South of Europe. Eur Psychiat 2012; 6 (27): 442–4. 5. Kimura H, Kanahara N, Watanabe H, Iyo M. Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine super sensitivity psychosis. Schizophr Res 2013; 145: 130–1. 6. Manrique-Garcia E, Zammit S, Dalman C et al. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. Psychol Med 2012; 6 (42): 1321–8.